iRegene Therapeutics

iRegene Therapeutics is at the forefront of biotechnology research, dedicated to re-defining medicine for the coming generation. With a passionate team, iRegene Therapeutics is committed to developing first-in-class therapies for patients suffering from major incurable diseases. The company prioritizes making fast-acting and disease-reversing therapies accessible to patients to the greatest extent possible.

iRegene Therapeutics specializes in researching and developing proprietary chemically-derived allogeneic cell therapy for degenerative diseases such as Parkinson’s Disease, retinal degenerative diseases, and ischemic stroke. Their leading pipeline, NouvNeu001 for Parkinson’s Disease, is scheduled to initiate Phase I clinical trials. iRegene Therapeutics operates from multiple locations, including its primary address at 9 Gaokeyuan 3rd Rd, East Lake High-Tech Development Zone, Wuhan, Hubei, CN; 160 Robinson Road #14-04 Singapore Business Federation Centre, Singapore, 068914, SG; and 218 Sang Tian Rd. BLDG 2 Rm.501 BioBAY Phase 2, Suzhou Industrial Park, Suzhou, Jiangsu 215000, CN.

iRegene Therapeutics leverages expertise in deep learning, organoids, regenerative medicine, neurology, stem cell therapy, cardiology, and Chem+AI to advance its innovative therapeutic solutions. The team is actively expanding its capabilities and welcomes you to discover more about iRegene Therapeutics. We invite the manager of iRegene Therapeutics to create a customized and exclusive company showcase and product listing on our platform.